

RUSH Institutional Biosafety Committee (IBC)	
Meeting Date	May 27, 2026
Meeting Time	12:00 PM – 1:00 PM
Meeting Type	Virtual via Microsoft Teams
IBC Members Present	1. Amarjit Viridi, Ph.D. (IBC Chair) 2. Ed R. Blazek, Ph.D., SM (NRCM) (BSO) 3. João Mamede, Ph.D. (IBC Member / Recombinant DNA Technologies) 4. Rebecca ‘Bex’ Ober, D.V.M. (Senior Director, Comparative Research Center) 5. Liudmila Romanova, Ph.D. (IBC Member / Expertise Neurological Sciences) 6. Jennifer Strong (<i>ex officio</i> Non-Voting / Research Compliance) 7. Derrick Swistak (Non-Affiliated Member) 8. Brett Williams, M.D. (IBC Member / Infectious Disease Physician)
Quorum	Quorum was declared by the Chair. The IBC has nine voting members, and five members are required to conduct business.
Other Individuals in Attendance	1. Christine VanTubbergen, MPH (Program Manager, Office of Research Affairs)
Call to Order	The Chair called the meeting to order at 12:00 PM.
Conflicts of Interest	The Chair reminded all members present to identify any conflicts of interest as each application is reviewed.
Review and Approval of Previous Meeting Minutes	April 22, 2026 Motion: Approve the minutes as circulated. Votes: 6-0-0-0 (for-against-abstain-recuse)

Review of Prior Business		
PI Name & ORA #	Application	Approval Date
Berry-Kravis, Elizabeth, M.D. 26013003-IBC01	Initial Application	04/22/2026
Patel, Neepa, M.D. 23091102-IBC07	Amendment 06	04/23/2026
Asimakopoulos, Fotios, M.D. 25040806-IBC01	Initial Application	04/24/2026
Asimakopoulos, Fotios, M.D. 25110204-IBC01	Initial Application	04/24/2026
Killinger, Bryan, Ph.D. 25011701-IBC01	Initial Application	05/04/2026
Patel, Neepa, M.D. 23091102-IBC07	Continuing Review 01	05/04/2026
Berry-Kravis, Elizabeth, M.D. 23092006-IBC18	Amendment 15	05/07/2026
Hall, Deborah, M.D. 19010804-IBC32	Amendment 36	05/07/2026
Reisz, Peter, M.D. 23082101-IBC01 through -09	Closed	05/13/2026
Nathan, Sunita, M.D. 21060306-IBC28	Amendment 24	05/14/2026
Tammineni, Eshwar Reddy, Ph.D. 25011601-IBC01	Withdrawn	05/27/2026
Berry-Kravis, Elizabeth, M.D. 24090903-IBC08	Amendment 06	05/27/2026

New Business	Ahrens-Nicklas, R. C., Kotch, C., Roche, A. M., Everett, J. K., Reddy, S., Santi, M., Madsen, P. J., Martos-Rus, C., Yrigollen, C. M., Small, J. C., McCague, S., Davidson, B. L., Samelson-Jones, B. J., Surrey, L. F., Li, M., Ficicioglu, C., Wang, R., Bushman, F. D., & George, L. A. (2026). Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery. <i>The New England journal of medicine</i>, 394(21), 2126–2133. https://doi.org/10.1056/NEJMoa2601608 The Committee was convened to discuss the results of this article and the implications for studies utilizing AAV vectors. In short, this article describes the first documented case of AAV genomic integration and oncogenesis in a human patient. The patient had previously received an intracisternal magna administration of AAV serotype 9 gene therapy for treatment of severe mucopolysaccharidosis type I (MPSI). Molecular analysis of the tumor demonstrated AAV integration. The tumor was successfully resected, and the patient has continued to have advanced cognitive function for his age, indicating mitigation of MPSI. Due to these findings, oncogenesis should now be listed as a known adverse effect of AAV vectors regardless of serotype. • A motion was made to: • Present this evidence to all principal investigators of AAV vector studies and require that study ICFs include this case of cancer caused by AAV integration into the genome as an observed risk of AAV-mediated gene therapy. ICFs must be revised within one month of IBC notification of PIs. • Other study documents (e.g., study protocol, Investigators’ Brochure) must be revised to reflect the risk of AAV carcinogenesis within 3 months of IBC notification. • The IRB will be notified of the above requirements and of the studies affected at the same time as PI notification. <u>Votes:</u> • 6-0-0-0 Conflicts of Interest: None
Review of Incidents	Nothing to report.
Inspections/Ongoing Oversight	Nothing to report.
IBC Training	Nothing to report.
Public Comments	There were no public comments.
Adjournment	The Chair moved to adjourn the meeting at 12:31 PM The next meeting scheduled is for June 24, 2026 at 12:00 PM via Microsoft Teams.